ALXN - Alexion Pharmaceuticals hikes FY20 FY25 revenue guidance

Alexion Pharmaceuticals (ALXN) increases its FY20 revenue guidance by more than $200M from $5.68B previous guidance.2025 Guidance: Net revenue target increased to $9B-$10B vs. $7.86B previous estimate, and at least 10% revenue compound annual growth rate through 2025 and beyond.Also, ALXN expects to return at least $3B to shareholders through multi-year stock buyback program.Alexion’s pipeline now includes more than 20 development programs, up from four at the end of 2017, with the potential for 10 promising launches by 2023. The company is on track to produce more than five novel INDs by 2025, including two this year.Shares are up 2% PM.

For further details see:

Alexion Pharmaceuticals hikes FY20, FY25 revenue guidance